Overview

Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks

Status:
Completed
Trial end date:
2020-01-24
Target enrollment:
Participant gender:
Summary
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fingolimod Hydrochloride